INCB018424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera/essenlial thrombocythemia myelofibrosis (Post-PV/ET MF)

被引：13
|
作者：
Verstovsek, Srdan [1 ]
Kantarjian, Hagop [1 ]
Pardanani, Animesh
Thomas, Deborah [1 ]
Cortes, Jorge [1 ]
Mesa, Ruben [2 ]
Redman, John [3 ]
Staschen, Carl-Michael [3 ]
Fridman, Jordan [3 ]
Vaddi, Kris [3 ]
Tefferi, Ayalew [2 ]
机构：
[1] MD Anderson Canc Ctr, Leukemia Dept, Houston, TX USA
[2] Mayo Clin, Dept Hematol, Rochester, MN USA
[3] Incyte Corp, Wilmington, DE USA
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.558.558
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
558
引用
收藏
页码：171A / 171A
页数：1
相关论文
共 50 条
  • [41] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    Quintas-Cardama, A.
    Tong, W.
    Kantarjian, H.
    Thomas, D.
    Ravandi, F.
    Kornblau, S.
    Manshouri, T.
    Cortes, J. E.
    Garcia-Manero, G.
    Verstovsek, S.
    LEUKEMIA, 2008, 22 (05) : 965 - 970
  • [42] A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis
    A Quintás-Cardama
    W Tong
    H Kantarjian
    D Thomas
    F Ravandi
    S Kornblau
    T Manshouri
    J E Cortes
    G Garcia-Manero
    S Verstovsek
    Leukemia, 2008, 22 : 965 - 970
  • [43] Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/ Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2022, 140 : 6844 - 6846
  • [44] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan P.
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit
    Bose, Prithviraj
    CANCER RESEARCH, 2023, 83 (08)
  • [45] A phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Bewersdorf, Jan Philipp
    Verstovsek, Srdan
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael J.
    Rampal, Raajit
    Bose, Prithviraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [46] A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Bewersdorf, Jan Philipp
    Derkach, Andriy
    Masarova, Lucia
    Pemmaraju, Naveen
    Stein, Eytan M.
    Mauro, Michael
    Rampal, Raajit K.
    Bose, Prithviraj
    BLOOD, 2023, 142
  • [47] A PHASE II STUDY OF VORINOSTAT (MK-0683) IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF) AND POST-POLYCYTHAEMIA VERA MYELOFIBROSIS (PPV-MF)
    Andersen, C.
    Mortensen, N.
    Vestergaard, H.
    Bjerrum, O.
    Klausen, T.
    Hasselbalch, H.
    HAEMATOLOGICA, 2013, 98 : 120 - 120
  • [48] A Novel Prognostic Model Including Cytogenetic and Molecular Data in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Datoguia, Tarcila Santos
    Goncalves, Giulliana A. R.
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [49] Prognostic Impact of Activating Mutations of the NRAS/KRAS Genes in Patients with Primary and Post-Essential Thrombocythemia (ET)/Polycythemia Vera (PV) Myelofibrosis (MF)
    Santos, Fabio P. S.
    Getta, Bartlomiej
    Masarova, Lucia
    Famulare, Christopher
    Schulman, Jessica
    Puga, Renato D.
    Alves Paiva, Raquel de Melo
    Hamerschlak, Nelson
    Kantarjian, Hagop M.
    Levine, Ross L.
    Campregher, Paulo Vidal
    Rampal, Raajit K.
    Verstovsek, Srdan
    BLOOD, 2018, 132
  • [50] Interim Analysis of Registry of Ruxolitinib Treatment in Patients with Intermediate-2 or High Risk Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) in Taiwan
    Hou, Hsin-An
    Lin, Chien-Chin
    Kuo, Ming-Chung
    Lin, Shyuann-Yuh
    Gau, Jyh-Pyng
    Wang, Ming-Chung
    Chang, Ming-Chih
    Chen, Tsung-Chih
    Yeh, Su-Peng
    Chen, Yeu-Chin
    Huang, Cih-En
    Chen, Chieh-Wen
    Lee, Yee-Ming
    Ku, Fan-Chen
    Shih, Lee-Yung
    BLOOD, 2019, 134
12345